
- /
- Supported exchanges
- / US
- / ACRS.NASDAQ
Aclaris Therapeutics Inc (ACRS NASDAQ) stock market data APIs
Aclaris Therapeutics Inc Financial Data Overview
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Aclaris Therapeutics Inc data using free add-ons & libraries
Get Aclaris Therapeutics Inc Fundamental Data
Aclaris Therapeutics Inc Fundamental data includes:
- Net Revenue: 17 777 K
- EBITDA: -53 988 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-06
- EPS/Forecast: -0.29
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aclaris Therapeutics Inc News

Aclaris Therapeutics at HCW Conference: Strategic Moves and Future Plans
On Monday, 30 June 2025, Aclaris Therapeutics (NASDAQ:ACRS) presented at the HCW Annual Inflammation & Immunology Virtual Conference 2025. The development-stage biotech company, led by CEO Dr. Neil Wa...


Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflamma...

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflamma...

Aclaris Therapeutics initiates Phase 1 trial for ATI-052 antibody
Investing.com - Aclaris Therapeutics (NASDAQ:ACRS) has launched a placebo-controlled Phase 1a/1b program for its bispecific antibody ATI-052, the company announced Monday. The trial will evaluate the...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.